Next phase of trial for bladder Will be interesting to see the treatment efficacy as more patients are treated. We may find that with 100 patients that efficacy is 75% and with 500 patients the efficacy rate is reduced to 50% and at 2000 patients efficacy is 25%. I have seen this type of scenario before in different treatments. This will reflect itself in the stock price. Even a 25% rate would be more efficient than what is currently available.